Women's Health Platform Integrated Wearable Data
The Xella Health platform now syncs with Oura devices to help users track biomarkers and address potential diagnostic delays.
Updated on Sept. 28, 2026 in Women’s Health
Live Poll
Do you trust that new health-tech platforms can improve the quality of diagnostic care for women?
Xella Health has integrated its precision diagnostics platform with the wearable company Oura to aggregate biometric data for personalized care plans. The platform screens for over 130 conditions and aims to bridge diagnostic gaps for women, though service is currently limited in some U.S. states.
Why it matters
Women are frequently diagnosed years later than men, a disparity documented in large-scale studies. By pairing biometric trends with diagnostic screening, this integration aims to provide the longitudinal context clinicians need to identify symptoms like pelvic pain and fatigue earlier.
A University of Copenhagen study of 6.9 million people found that women are diagnosed an average of four years later than men across 770 disease types. This evidence highlights the broader context of diagnostic delays that Xella Health seeks to mitigate through its new data-sharing capabilities.
The players
Xella Health
A women's precision health company offering diagnostic screening for over 130 conditions.
Oura
A wearable technology company that provides health tracking data and currently manages the Menopause Impact Scale.
The details
The integration allows Oura devices to share data including heart rate variability, sleep quality, body temperature, recovery metrics, and menstrual cycle information. Xella uses this information to map relationships across more than 100 biomarkers simultaneously. By tracking these metrics against an individual's own baseline, the system attempts to flag shifts in health trajectories that might warrant clinical review for conditions like endometriosis.
Timeline
May 2026: Oura launched its Menopause Impact Scale.
September 23, 2026: Xella announced the integration with Oura.
End of 2026: Expected market launch of Xella endometriosis risk tool.
Health Landscape
This integration follows a long-term shift away from the 1977 FDA rule excluding women from drug trials, which was eventually reversed in 1993. The move reflects a broader trend of leveraging digital biomarkers to address longstanding gaps in women's health research and diagnosis.
If you are considering a membership, note that Xella is currently unavailable to residents of New York and New Jersey until 2027. Review your personal health history and any persistent symptoms like pelvic pain with your physician to determine if digital biomarker tracking is appropriate for your care.
The takeaway
Diagnostic delays remain a significant issue in women's healthcare, often persisting for years. If you notice unusual changes in your own health trends or persistent symptoms, discuss these with your primary care provider to ensure you are receiving timely screening and care.
What happens next
Xella expects to bring a CLIA-route endometriosis risk tool to market before the end of 2026.
Further reading
Learn more about the latest innovations in Women’s Health.
Source note: This article includes information reported by Forbes.
Live Poll
Do you trust that new health-tech platforms can improve the quality of diagnostic care for women?
